TABLE 2.
Longitudinal Changes in Patient Characteristics by Fibrosis Progression by ≥15% Increase in MRE
| Change in Patient Characteristics | <15% Increase MRE (n = 82) | ≥15% Increase MRE (n = 20) | P |
|---|---|---|---|
| Demographic and biochemical | |||
| BMI (kg/m2) | 0 (2.1) | 0 (1.1) | 0.58 |
| AST (U/l) | −3 (20) | 5 (17) | 0.08 |
| ALT (U/l) | −3 (27) | 0 (50.5) | 0.22 |
| Alkaline phosphatase (U/l) | 1 (18) | 5.5 (19.5) | 0.07 |
| Total bilirubin (mg/dL) | 0 (0.2) | 0 (0.2) | 0.59 |
| Albumin (g/dL) | 0 (0.3) | 0 (0.3) | 0.74 |
| HOMA-IR | 0.9 (5.4) | 1.1 (3.3) | 0.79 |
| Triglycerides (mg/dL) | 3 (78) | −17 (46) | 0.08 |
| Total cholesterol (mg/dL) | 2.5 (35) | −12 (37) | 0.13 |
| HDL (mg/dL) | 1 (8) | 3 (10) | 0.99 |
| LDL (mg/dL) | −2 (31) | −2 (28) | 0.53 |
| Platelet count (109/L) | 1 (45) | 3.5 (60) | 0.62 |
| Histology | |||
| Fibrosis progression,* n (%) | 15 (20.0) | 8 (47.1) | 0.03 |
| Fibrosis improvement,† n (%) | 17 (28.8) | 4 (25.0) | 1.00 |
| No change in fibrosis, n (%) | 50 (61.0) | 8 (40.0) | 0.09 |
| Steatosis grade | 0 (1) | 0 (1.5) | 0.21 |
| Lobular inflammation grade | 0 (1) | 0 (2) | 0.73 |
| Ballooning grade | 0 (1) | 0 (1) | 0.48 |
| NAS | −1 (2) | 0 (3) | 0.14 |
| Clinical prediction rules | |||
| FIB-4 | −0.1 (0.4) | 0.1 (0.6) | 0.07 |
| NFS | −0.1 (0.7) | 0.2 (1.1) | 0.18 |
| Imaging | |||
| LSM on MRE (kPa) | −0.3 (0.6) | 0.9 (0.8) | <0.001 |
All values are median (IQR) unless otherwise specified. Bold indicates significance.
Fibrosis progression limited to patients without cirrhosis at baseline, for <15% increase on MRE and ≥15% increase on MRE n = 75 and n = 17, respectively.
Fibrosis improvement limited to patients with fibrosis at baseline, for <15% increase on MRE and ≥15% increase on MRE n = 59 and n = 16, respectively.
Abbreviations: HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment method for insulin resistance, (fasting insulin [microunits per milliliter] × fasting glucose [millimoles per liter])/22.5; LDL, low-density lipoprotein; LSM, liver stiffness measurement; NAS, NAFLD activity score.